sb-222200 and Mouth-Neoplasms

The neurokinin 3 receptor (NK-3R) is differentially expressed in the central nervous system including cases of human oral squamous cell carcinoma. However, the role of NK-3R signaling in oral squamous cell carcinoma is not well known.. NK-3R expression in surgically resected oral squamous cell carcinoma was examined immunohistochemically and the strength of the expression was quantified. We evaluated the function of NK-3R signaling using NK-3R antagonist in human oral squamous cell carcinoma bone invasion mouse model.. NK-3R was significantly expressed in tumor cells that had invaded the bone matrix compared to the oral side tumor cells. SB222200, a selective antagonist of NK-3R, significantly suppressed the radiographic osteolytic lesion and tumorigenesis.. NK-3R signaling is a potential target for the treatment of oral squamous cell carcinoma in cases of bone destruction.

Topics: Animals; Apoptosis; Bone Resorption; Carcinoma, Squamous Cell; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Prognosis; Quinolines; Receptors, Neurokinin-3; Retrospective Studies; Tumor Cells, Cultured; Xenograft Model Antitumor Assays